Documenta Ophthalmologica

, Volume 84, Issue 3, pp 237–246

Negative-type electroretinogram from cisplatin toxicity

  • Michael F. Marmor


A 68-year-old woman with ovarian cancer suffered a loss of visual acuity and color perception after inadvertent overdosage with the antineoplastic agent cisplatin. Her acuity returned to normal but a tritan color defect persisted more than a year later. Her electroretinogram was stable between 7 weeks and 15 months after cisplatin administration, with a negative-type scotopic response, but also reduced cone b waves and a loss of some scotopic oscillatory potentials. With light stimuli between 10 and 100 ms in duration, the photopic on-responses were markedly reduced while the off-responses were normal or close to it. This case suggests that cisplatin may selectively injure on-pathways in the retina and indicates the need to expand the list of disorders that may cause a negative-type electroretinogram.

Key words

Cancer-associated retinopathy Cisplatin Electroretinogram Night blindness Off-response On-response 



congenital stationary night blindness


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schubert G, Bornschein H. Beitrag zur Analyse des menschlichen Elektroretinogramms. Ophthalmologica 1952; 123: 396–413.PubMedGoogle Scholar
  2. 2.
    Carr RE. Congenital stationary nightblindness. Trans Am Ophthalmol Soc 1974; 72: 448–87.PubMedGoogle Scholar
  3. 3.
    Miyake Y, Yagasaki K, Horiguchi M, Kawase Y, Kanda T. Congenital stationary night blindness with negative electroretinogram. Arch Ophthalmol 1986; 104: 1013–20.PubMedGoogle Scholar
  4. 4.
    Ripps H, Carr RE, Siegel IM, Greenstein VC. Functional abnormalities in vincristineinduced night blindness. Invest Ophthalmol Vis Sci 1984; 25: 787–94.PubMedGoogle Scholar
  5. 5.
    Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988; 106: 307–11.PubMedGoogle Scholar
  6. 6.
    Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MOM. ‘On’ response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 1992; 33: 477–83.PubMedGoogle Scholar
  7. 7.
    Miyake Y, Yagasaki K, Horiguchi M, Kawase Y. On- and off-responses in photopic electroretinogram in complete and incomplete types of congenital stationary night blindness. Jpn J Ophthalmol 1987; 31: 81–7.PubMedGoogle Scholar
  8. 8.
    Houchin KW, Purple RL, Wirtschafter JD. X-linked congenital stationary night blindness and depolarizing bipolar system dysfunction. Invest Ophthalmol Vis Sci 1991; 32(suppl.): 1229.Google Scholar
  9. 9.
    Young RSL. Low-frequency component of the photopic ERG in patients with X-linked congenital stationary night blindness. Clin Vision Sci 1991; 6: 309–15.Google Scholar
  10. 10.
    Marmor MF, Arden GB, Nilsson SE, Zrenner E. Standard for clinical electroretinography. Arch Ophthalmol 1989; 107: 816–9. Reprinted with permission in Doc Ophthalmol 1989; 73(4): 303–11.PubMedGoogle Scholar
  11. 11.
    Daw NW, Jensen RJ, Brunken WJ. Rod pathways in mammalian retinae. Trends Neurosci 1990; 13: 110–5.PubMedGoogle Scholar
  12. 12.
    Ripps H. Night blindness revisited. From man to molecules. Invest Ophthalmol Vis Sci 1982; 23: 588–609.PubMedGoogle Scholar
  13. 13.
    Krill AE, Martin D. Photopic abnormalities in congenital stationary nightblindness. Invest Ophthalmol 1971; 10: 625–36.PubMedGoogle Scholar
  14. 14.
    Ripps H, Mehaffey L III, Siegel IM, Niemeyer G. Vincristine-induced changes in the retina of the isolated arterially-perfused cat eye. Exp Eye Res 1989; 48: 771–90.PubMedGoogle Scholar
  15. 15.
    Lachapelle P, Little JM, Polomeno RC. The photopic electroretinogram in congenital stationary night blindness with myopia. Invest Ophthalmol Vis Sci 1983; 24: 442–50.PubMedGoogle Scholar
  16. 16.
    Wilding G, Caruso R, Lawrence TS, Ostchega Y, Ballintine EJ, Young RC, Ozols RF. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985; 3: 1683–9.PubMedGoogle Scholar
  17. 17.
    Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tomsak RL. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985; 92: 402–6.PubMedGoogle Scholar
  18. 18.
    Kupersmith MJ, Frohman LP, Choi IS, Foo SH, Hiesinger E, Berenstein A, Wise A, Carr RE, Ransohoff J. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988; 38: 284–9.PubMedGoogle Scholar
  19. 19.
    Kupersmith MJ, Seiple WH, Holopigian K, Noble K, Hiesiger E, Warren F. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992; 113: 435–8.PubMedGoogle Scholar
  20. 20.
    Greenberg D, Fishman G, Tripathi R, Tripathi B, Peyman GA. The effects of intravitreal cisplatinum. Invest Ophthalmol Vis Sci 1985; 26(suppl): 60.Google Scholar
  21. 21.
    Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness is caused by photoreceptor degeneration as a remote effect on cancer. Am J Ophthalmol 1976; 81: 606–13.PubMedGoogle Scholar
  22. 22.
    Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration. Arch Ophthalmol 1983; 101: 564–9.PubMedGoogle Scholar
  23. 23.
    Perry MC, ed. The chemotheraphy source book. Baltimore: Williams & Wilkins, 1992.Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Michael F. Marmor
    • 1
  1. 1.Department of OphthalmologyStanford University School of MedicineStanfordUSA

Personalised recommendations